6Wacker B, Nagrani T, Weinberg J,et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase studies[J]. Clin Cancer Res,2007,13( 13):3913-3921.